相关实验视频

Updated: Jan 7, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

在多发性骨髓瘤中对双特异性抗体的现状和未来前景

Sheilabi Seeburun¹

¹Rutgers, The State University of New Jersey, New Brunswick, United States. sheilabiseeburun@hotmail.com.

Journal of the Egyptian National Cancer Institute

|December 28, 2025

概括

双特异性抗体 (BsAbs) 为多发性骨髓瘤 (MM) 提供了一种新的免疫疗法,在复发性/耐药患者中显示出高响应率. 新兴的三种特异性抗体也显示出显著的疗效,推动了MM治疗的前进,实现了潜在的治愈.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

多发性骨髓瘤 (MM) 是一种无法治愈的血细胞癌.
目前的治疗方法包括蛋白酶体抑制剂,免疫调节药物和单克隆抗体.
双特异性抗体 (BsAbs) 是一种新的免疫治疗方法.

研究的目的:

审查BsAbs在MM中的机制,临床发展,疗效和安全性.
分析BsAbs和三种特异性抗体对复发性/耐药性MM (RRMM) 治疗的影响.
探索未来的方向,抵抗策略和MM中的BsAbs组合方案.

主要方法:

对MM中BsAbs和三种特异性抗体的最近临床试验数据的审查.
分析疗效 (总体响应率,严格的完整响应,MRD阴性) 和安全概况.
综合有关作用机制和治疗策略的信息.

主要成果:

最近获得FDA批准的BsAbs (teclistamab,talquetamab,elranatamab,linvoseltamab) 在RRMM中显示出高的整体响应率 (ORR>60%).
塔尔基塔马布实现了74%的ORR,即使是在用T细胞重定向疗法预先治疗的患者中.
新兴的三特异性抗体显示ORR高达75%,具有深度反应,包括MRD阴性.

结论:

BsAbs已经改变了RRMM的治疗场景.
三种特异性抗体显示出有希望的疗效和深度反应.
优化BsAb组合和测序对于改善患者的治疗结果和推进MM治疗至关重要.

关键词:

这就是为什么BCMABCMABCMA.双特异性抗体双特异性抗体埃尔拉纳塔马巴的意思是免疫治疗是一种免疫疗法.多发性骨髓瘤是一种多发性骨髓瘤.五度耐火的MMMM可以使用.复发 / 耐火性复发 / 耐火性我们谈论了它.机械师是什么意思三特异性抗体三特异性抗体

更多相关视频

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...